Andrzej Czyrski
Overview
Explore the profile of Andrzej Czyrski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sznek B, Czyrski A
J Chromatogr A
. 2025 Jan;
1743:465686.
PMID: 39847982
This study aimed to analyze the impact of acidic conditions on the recovery of ciprofloxacin and levofloxacin for cloud point extraction with the Design of Experiments and Artificial Neural Networks....
2.
Adamiszak A, Czyrski A, Sznek B, Grzeskowiak E, Bienert A
Pharmaceuticals (Basel)
. 2025 Jan;
17(12.
PMID: 39770521
This study aimed to develop an optimized and wide concentration range HPLC-UV method for fluconazole (FLU) determination and its adaptation for pharmacokinetics (PK) studies in the pediatric population. The following...
3.
Sznek B, Stasiak A, Czyrski A
Polim Med
. 2024 Nov;
54(2):113-116.
PMID: 39610258
Developing the analytical procedure requires estimating what independent variables will be tested and at what levels. There are statistical models that enable the optimization of the process. They involve statistical...
4.
Swiatek S, Czyrski A
Crit Rev Anal Chem
. 2024 Aug;
:1-27.
PMID: 39155524
Psychoactive substances pose significant challenges and dangers to society due to their impact on perception, mood, and behavior, leading to health and life disturbances. The consumption of these substances is...
5.
Szkutnik-Fiedler D, Szalek E, Otto F, Czyrski A, Karazniewicz-Lada M, Wolc A, et al.
Pharmacol Rep
. 2024 Apr;
76(5):1184-1195.
PMID: 38632186
Background: Regorafenib is used in the treatment of colorectal cancer and hepatocellular carcinoma. Due to the co-morbidity of hyperlipidemia in these conditions, statins, including atorvastatin, are used as potential adjuvant...
6.
Michalowska A, Kupczyk O, Czyrski A
Pharmaceutics
. 2023 Jun;
15(6).
PMID: 37376221
This study aimed to analyze the factors that impact the cloud point extraction of ciprofloxacin, levofloxacin, and moxifloxacin. The following independent variables were analyzed: Triton X-114 concentration, NaCl concentration, pH,...
7.
Resztak M, Sobiak J, Czyrski A
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959272
The review includes studies dated 2011-2021 presenting the newest information on voriconazole (VCZ), mycophenolic acid (MPA), and vancomycin (VAN) therapeutic drug monitoring (TDM) in children. The need of TDM in...
8.
Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka F
Pharmaceutics
. 2021 Nov;
13(11).
PMID: 34834376
Second generation triazoles are widely used as first-line drugs for the treatment of invasive fungal infections, including aspergillosis and candidiasis. This class, along with itraconazole, voriconazole, posaconazole, and isavuconazole, is...
9.
Czyrski A
Spectrochim Acta A Mol Biomol Spectrosc
. 2021 Sep;
265:120343.
PMID: 34500409
Lipophilicity plays a significant role in the permeability of the drugs through cell membranes and impacts the drug activity in the human body. In this paper, the spectrophotometric method was...
10.
Karbownik A, Szkutnik-Fiedler D, Czyrski A, Kostewicz N, Kaczmarska P, Bekier M, et al.
Pharmaceutics
. 2020 Jul;
12(7).
PMID: 32605304
The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like...